{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:51:18Z","timestamp":1790819478639,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.atherosclerosis.2025.120588","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T16:16:17Z","timestamp":1764000977000},"page":"120588","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Effect of alirocumab on coronary plaque stratified by atherothrombotic risk"],"prefix":"10.1016","volume":"412","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4630-9815","authenticated-orcid":false,"given":"Yasushi","family":"Ueki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Kakizaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuhiko","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Itagaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Losdat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Shibutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"H\u00e4ner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"B\u00e4r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan F.","family":"Iglesias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert-Jan","family":"van Geuns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Spirk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost","family":"Daemen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Engstr\u00f8m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos C.","family":"Koskinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0824-3026","authenticated-orcid":false,"given":"Lorenz","family":"R\u00e4ber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2025.120588_bib1","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2025.120588_bib2","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2025.120588_bib3","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","article-title":"Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk)","volume":"137","author":"Bonaca","year":"2018","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2025.120588_bib4","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.jacc.2019.03.013","article-title":"Alirocumab in patients with polyvascular disease and recent acute coronary syndrome: ODYSSEY OUTCOMES trial","volume":"74","author":"Jukema","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120588_bib5","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1161\/CIRCULATIONAHA.118.034309","article-title":"Clinical benefit of evolocumab by severity and extent of coronary artery disease","volume":"138","author":"Sabatine","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2025.120588_bib6","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1001\/jamacardio.2020.0882","article-title":"Efficacy of evolocumab on cardiovascular outcomes in patients with recent myocardial infarction: a prespecified secondary analysis from the FOURIER trial","volume":"5","author":"Gencer","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120588_bib7","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA Guideline for the management of patients with chronic coronary disease: a report of the American heart association\/american college of cardiology joint committee on clinical practice guidelines","volume":"148","author":"Virani","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2025.120588_bib8","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American college of cardiology\/american heart association task force on clinical practice guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120588_bib9","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1161\/CIRCULATIONAHA.119.042551","article-title":"Risk categorization using new American college of cardiology\/american heart association guidelines for cholesterol management and its relation to alirocumab treatment following acute coronary syndromes","volume":"140","author":"Roe","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2025.120588_bib10","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jacc.2016.11.070","article-title":"Atherothrombotic risk stratification and ezetimibe for secondary prevention","volume":"69","author":"Bohula","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120588_bib11","article-title":"Effect of alirocumab added to high-intensity Statin therapy on coronary atherosclerosis in patients with acute myocardial infarction","author":"R\u00e4ber","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2025.120588_bib12","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ahj.2021.04.006","volume":"238","author":"Zanchin","year":"2021","journal-title":"Am Heart J"},{"key":"10.1016\/j.atherosclerosis.2025.120588_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2023.08.019","article-title":"Concomitant coronary atheroma regression and stabilization in response to lipid-lowering therapy","author":"Biccire","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120588_bib14","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1161\/CIR.0000000000000297","article-title":"The agenda for familial hypercholesterolemia: a scientific statement from the American heart association","volume":"132","author":"Gidding","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2025.120588_bib15","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jamacardio.2023.2731","article-title":"Mancini GBJ atherosclerotic coronary plaque regression and risk of adverse cardiovascular events: a systematic review and updated meta-regression analysis","volume":"8","author":"Iatan","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120588_bib16","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jacc.2025.04.070","article-title":"Plaque vulnerability and cardiovascular risk factor burden in acute coronary syndrome: an optical coherence tomography analysis","volume":"86","author":"Covani","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120588_bib17","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jacc.2008.03.051","article-title":"Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials","volume":"52","author":"Nicholls","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120588_bib18","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1253\/circj.CJ-09-0766","volume":"74","author":"Hiro","year":"2010","journal-title":"Circ J"},{"key":"10.1016\/j.atherosclerosis.2025.120588_bib19","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/1475-2840-11-87","volume":"11","author":"Daida","year":"2012","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.atherosclerosis.2025.120588_bib20","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12933-017-0637-0","article-title":"Plaque volume and plaque risk profile in diabetic vs. non-diabetic patients undergoing lipid-lowering therapy: a study based on 3D intravascular ultrasound and virtual histology","volume":"16","author":"Kovarnik","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.atherosclerosis.2025.120588_bib21","doi-asserted-by":"crossref","first-page":"181","DOI":"10.5551\/jat.54726","article-title":"Effects of statin plus ezetimibe on coronary plaques in acute coronary syndrome patients with diabetes mellitus: sub-analysis of PRECISE-IVUS trial","volume":"28","author":"Fujisue","year":"2021","journal-title":"J Atherosclerosis Thromb"},{"key":"10.1016\/j.atherosclerosis.2025.120588_bib22","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.124.016683","article-title":"Association of Lipoprotein(a) with changes in coronary atherosclerosis in patients treated with alirocumab","volume":"17","author":"Koskinas","year":"2024","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.atherosclerosis.2025.120588_bib23","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1253\/circj.CJ-23-0031","article-title":"Clinical significance of coronary healed plaques in stable angina pectoris patients undergoing percutaneous coronary intervention","volume":"87","author":"Kimura","year":"2023","journal-title":"Circ J"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915025014868?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915025014868?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T13:25:24Z","timestamp":1781270724000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915025014868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":23,"alternative-id":["S0021915025014868"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.120588","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of alirocumab on coronary plaque stratified by atherothrombotic risk","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.120588","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"120588"}}